[Expert consensus on clinical diagnosis and treatment of portal hypertension with hepatocellular carcinoma (2022)].

At present, there is no uniform standard for diagnosis and treatment of portal hypertension complicated with hepatocellular carcinoma internationally. Although in recent years, with the significant advances of surgical technique and the positive progress of targeted and immunotherapy in the field of hepatocellular carcinoma, the survival of hepatocellular carcinoma patients has improved, but the risk of surgery in patients with portal hypertension complicated with hepatocellular carcinoma remains high, and surgical treatment is still controversial. Therefore, based on the existing evidence, the Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association has organized relevant experts to develop the consensus on clinical diagnosis and treatment of portal hypertension with hepatocellular carcinoma (2022) after full discussion. This consensus aims to provide the latest guidance for the standardized diagnosis and treatment of portal hypertension with hepatocellular carcinoma in China. Given that most portal hypertension originates from cirrhosis, this consensus only addresses the diagnosis and treatment of cirrhosis-related portal hypertension with hepatocellular carcinoma.目前，国内外对门静脉高压合并肝癌患者的诊疗尚无统一标准和规范。虽然随着手术技术的进步及靶向和免疫治疗在肝癌领域取得积极进展，肝癌患者的生存质量有所改善，但门静脉高压合并肝癌患者的手术风险仍较大，手术治疗仍有较多争议。为此，中华医学会外科学分会脾及门静脉高压外科学组基于现有循证医学证据，组织相关专家经过充分讨论，制定了本共识，旨在为我国门静脉高压合并肝癌患者的规范化诊疗提供最新的指导性建议。鉴于大部分门静脉高压源于肝硬化，故本共识仅涉及肝硬化相关门静脉高压合并肝癌的诊疗意见。.